Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) insider Mark A. Goldsmith sold 10,000 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $45.88, for a total value of $458,800.00. Following the transaction, the insider now owns 311,885 shares in the company, valued at $14,309,283.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Revolution Medicines Stock Performance
Shares of RVMD traded down $1.27 on Friday, reaching $44.00. The stock had a trading volume of 1,085,142 shares, compared to its average volume of 1,435,524. Revolution Medicines, Inc. has a 12-month low of $15.44 and a 12-month high of $48.61. The firm has a market capitalization of $7.26 billion, a price-to-earnings ratio of -11.73 and a beta of 1.44. The company has a 50-day simple moving average of $41.13 and a 200-day simple moving average of $35.56.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.05. During the same period in the prior year, the business posted ($0.72) EPS. The firm’s revenue was down 100.0% on a year-over-year basis. On average, analysts expect that Revolution Medicines, Inc. will post -3.21 EPS for the current fiscal year.
Analysts Set New Price Targets
Institutional Trading of Revolution Medicines
Several hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its position in shares of Revolution Medicines by 576.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,941 shares of the company’s stock valued at $543,000 after acquiring an additional 16,139 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Revolution Medicines by 34.0% in the fourth quarter. Arizona State Retirement System now owns 28,384 shares of the company’s stock valued at $814,000 after acquiring an additional 7,195 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Revolution Medicines by 45.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 80,405 shares of the company’s stock valued at $2,306,000 after acquiring an additional 25,160 shares in the last quarter. Strs Ohio lifted its position in shares of Revolution Medicines by 54.0% in the fourth quarter. Strs Ohio now owns 9,700 shares of the company’s stock valued at $278,000 after acquiring an additional 3,400 shares in the last quarter. Finally, Mackenzie Financial Corp purchased a new position in shares of Revolution Medicines in the fourth quarter valued at about $248,000. Institutional investors own 94.34% of the company’s stock.
Revolution Medicines Company Profile
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Featured Articles
- Five stocks we like better than Revolution Medicines
- What is the Shanghai Stock Exchange Composite Index?
- Should You Invest in Bitcoin? Pros and Cons
- Options Trading – Understanding Strike Price
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- Retail Stocks Investing, Explained
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.